

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Claus Schmidt Møller

Application No.: 10/667,040

Group Art Unit: 3762

Filed: September 22, 2003

Examiner: STIGELL, THEODORE J

For: Injection Device

**MISCELLANEOUS LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants wish to thank the Examiner for the in person interview on March 21, 2007 and for the brief telephone call on April 9, 2007 where the Examiner offered to allow all claims except claims 16-21, 30-35, and 43. Applicants' attorney offered to allow the Examiner to cancel these claims by Examiner's amendment. The Examiner expressed concerns about claim 43 because it invoked means plus function language and the Examiner was uncomfortable with allowing applicants to claim the subject matter using 112 6<sup>th</sup> paragraph language and noted that the **non** means-plus-function claim 42 was perfectly acceptable.

At the in person interview, Applicants' attorney discussed the pending claim with the Examiner and distinguished the Burroughs reference and other prior art in general by showing the Examiner how the Applicants's invention works. The NovoPen 4 device was shown the Examiner and it was contrasted with the prior art. It is show in figure sheet 1 of 3 attached hereto. Figure sheets 2 and 3 show other devices that were presented to the Examiner in complete and component form. At the interview, Applicants' attorney argued that the features of the claimed invention are not shown in the prior art.

In the event any extra fees are due, please charge these fees to Novo Nordisk Inc.  
Deposit Account No. 14-1447.

Respectfully submitted,

Date: April 9, 2007

*Marc A. Began*

Marc A. Began, Reg. No. 48,829  
Novo Nordisk, Inc.  
Customer Number 23650  
(609) 987-5800

Use the following customer number for all correspondence regarding this application

**23650**  
PATENT TRADEMARK OFFICE